Cbio A/S is a clinical stage cell therapy company started in 2019 focusing on Tumor Infiltrating Lymphocyte (TIL) therapy – the most promising cell therapy for solid tumors. We have licensed a clinically proven TIL product ‘novoleucel’ from world-leading academic institution, Herlev Hospital in Denmark and have developed a proprietary next-generation TIL manufacturing process with transformative potential. Our lead TIL therapy product, novoleucel, is now ready for clinical validation. We are located in Søborg (Copenhagen area), Denmark in a 1,000 m2 state-of-the-art facility where we develop and produce cell-based therapy products for clinical use.